- Home
- PAM vs SLNO Comparison
PAM vs SLNO Comparison
Compare PAM & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- SLNO
- Stock Information
- Founded
- PAM 1945
- SLNO 1999
- Country
- PAM Argentina
- SLNO United States
- Employees
- PAM N/A
- SLNO N/A
- Industry
- PAM Electric Utilities: Central
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PAM Utilities
- SLNO Health Care
- Exchange
- PAM Nasdaq
- SLNO Nasdaq
- Market Cap
- PAM 3.8B
- SLNO 3.8B
- IPO Year
- PAM N/A
- SLNO 2014
- Fundamental
- Price
- PAM $67.53
- SLNO $67.67
- Analyst Decision
- PAM Buy
- SLNO Strong Buy
- Analyst Count
- PAM 3
- SLNO 10
- Target Price
- PAM $85.83
- SLNO $112.50
- AVG Volume (30 Days)
- PAM 273.4K
- SLNO 1.6M
- Earning Date
- PAM 08-06-2025
- SLNO 08-06-2025
- Dividend Yield
- PAM N/A
- SLNO N/A
- EPS Growth
- PAM N/A
- SLNO N/A
- EPS
- PAM 0.33
- SLNO N/A
- Revenue
- PAM $1,875,000,000.00
- SLNO $32,656,999.00
- Revenue This Year
- PAM $135,871.60
- SLNO N/A
- Revenue Next Year
- PAM $26.02
- SLNO $175.39
- P/E Ratio
- PAM $8.49
- SLNO N/A
- Revenue Growth
- PAM N/A
- SLNO N/A
- 52 Week Low
- PAM $51.76
- SLNO $41.50
- 52 Week High
- PAM $97.55
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- PAM 39.74
- SLNO 35.70
- Support Level
- PAM $65.38
- SLNO $66.29
- Resistance Level
- PAM $71.14
- SLNO $70.74
- Average True Range (ATR)
- PAM 3.13
- SLNO 3.25
- MACD
- PAM -0.82
- SLNO -0.51
- Stochastic Oscillator
- PAM 16.09
- SLNO 18.40
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.